Advancing Research
by funding Grant Programs and Fellowships
Driving Innovation
by guiding studies such as the FAST Initiative, the SuperAgers Initiative, and the TAME Trial
Furthering the Field
by supporting the infrastructure of three NIA Initiatives and leading the Amplifying Geroscience Initiative.
Top Breakthroughs driven by AFAR Experts
Delaying Disease by Targeting Aging
Saving Costs by Extending Healthspan
What are the Hallmarks of Aging?
What is Geroscience?
What is the Longevity Dividend?
Aging is a leading risk factor for metabolic diseases. Fatty acid binding proteins (FABPs) have profound effects on chronic inflammation and metabolic diseases in mouse models obesity, diabetes, and cardiovascular disease. In previous research, it was demonstrated that the targeting of FABPs is effective in restoring health in rodents in both obesity-related disease models and in normal aging. In the proposed study, Dr. Li plans to characterize the mechanism by which the adipose tissue protein FABP4 negatively affects metabolism and healthspan. The completion of these studies would support the idea that an inhibitor of FABP is a possible approach for further translational development and application related to human aging, and shed light on the longevity-extending role of bioactive lipids.
